{Reference Type}: Case Reports
{Title}: Treatment of fungal infection on left ventricle assist device driveline exit site: a case report and systematic review.
{Author}: Brandão SMG;Biseli B;Ayub-Ferreira SM;Strabelli TMV;Bocchi EA;
{Journal}: J Wound Care
{Volume}: 32
{Issue}: 0
{Year}: 2023 Sep 1
{Factor}: 2.066
{DOI}: 10.12968/jowc.2023.32.Sup9a.cxc
{Abstract}: UNASSIGNED: The use of ventricular assist devices (VAD) is increasing; however, diagnosis and management of device complications, such as the driveline exit site (DES) being the portal of entry for fungal infection, is not well known.
UNASSIGNED: A systematic review involving searching PubMed (2005 to July 2020) was conducted. The case of a 43-year-old female patient who had a left VAD (LVAD) (HeartMate 3, Abbott, US) is also reported.
UNASSIGNED: The patient was successfully treated with ketoconazole cream and oral fluconazole for likely superficial DES fungal infections. We included 36 studies that met our inclusion criteria; however, only one was included in our review. In the literature, five cases of DES fungal infection were reported, with Candida being the only fungal pathogen.
UNASSIGNED: LVAD fungal infections are uncommon but can be responsible for high mortality rates, require a prolonged period of treatment, and can present a huge problem when surgical alternatives are not available. However, Candida species are most common. Fungal infections can only produce clear discharge, and so the classic definition of driveline infection based on purulent secretion can vary. Negative skin culture does not exclude the diagnosis of infection of the DES, and so empirical diagnosis may only be clinically based.